Financial Data and Key Metrics Changes - The company reported a combined revenue of $19.8 million for Q1 2025, with Hebsado sales in the U.S. contributing $18 million and ChemoSAT sales in Europe adding $1.8 million, compared to $2 million and $1.1 million respectively in Q1 2024 [5][15] - Gross margins improved to 86% in Q1 2025 from 71% in the same period last year [15] - Net income for Q1 2025 was $1.1 million, a significant turnaround from a net loss of $11.1 million in Q1 2024 [16] - Positive adjusted EBITDA for Q1 2025 was $7.6 million, compared to an adjusted EBITDA loss of $7.3 million in Q1 2024 [16] - The company ended the quarter with approximately $59 million in cash and investments, and positive operating cash flow of $2.2 million [16] Business Line Data and Key Metrics Changes - The company activated 19 treatment centers in the U.S. by the end of Q1 2025, with plans to reach 30 active centers by year-end [6][7] - Average treatments per center were approximately two per month in Q1, with expectations to remain just under two for the remainder of the year [8][27] Market Data and Key Metrics Changes - The European market for ChemoSAT experienced a 29% growth over the prior quarter, reaching $1.8 million, although it is not expected to be a significant revenue contributor in the short to medium term [9] - The company is focusing on expanding its presence in the U.S. market while managing reimbursement challenges in Europe [9][40] Company Strategy and Development Direction - The company aims to leverage cash from operations to support research and development initiatives for Hebsado beyond metastatic uveal melanoma patients [6] - The strategy includes expanding treatment centers and enhancing access for patients through the Hepcido KidAccess 360 platform [8] - The company is pursuing additional clinical trials for liver-dominant metastatic colorectal and breast cancer, with FDA clearance received for both trials [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the goal of 30 active centers by year-end, with a balanced approach to center activations throughout the year [22][24] - The company anticipates that the average monthly treatment per site will stabilize just under two for the remainder of the year due to the pace of new center activations [27] - Management highlighted the importance of clinical demand and engagement with oncologists and interventional radiologists in driving revenue growth [13] Other Important Information - The company has no outstanding debt obligations and has successfully raised $16.2 million through the exercise of Series F warrants [16][17] - The company is managing its European operations on a breakeven basis while focusing on generating clinical data [43] Q&A Session Summary Question: Update on center activations and expectations for Q2 - Management indicated that center activations may be more evenly distributed throughout the year than previously anticipated, with potential for two to three additional centers in Q2 [20][24] Question: Treatment frequency and center performance - Average treatment frequency is expected to stabilize around 4.1 treatments per patient, with a mix of organic and referred patients contributing to center performance [35][86] Question: R&D expenses and EBITDA expectations - R&D expenses are expected to increase significantly, with EBITDA margins projected to remain positive throughout the year despite rising operational costs [29][30] Question: European market growth and reimbursement - Management noted that while the European market is growing, reimbursement challenges remain, and additional resources will be allocated once reimbursement is secured [39][42] Question: Companion diagnostics and potential acquisitions - The company is open to exploring companion diagnostics or synergistic products but has not identified any suitable opportunities at this time [70][72]

Montrose Environmental Group (MEG) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Please note this event is being recorded. I would now like to turn the conference over to Adrienne Griffin, Senior Vice President, Investor Relations and Treasury. Please go ahead. Speaker1 Thank you, operator. Welcome to our first quarter twenty twenty five earnings call. Joining me on the call are Vijay Mantafergata, our President and Chief Executive Officer and Alan Dix, our Chief Financial Officer. During our prep ...

Hut 8 (HUT) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good day. Thank you for standing by. Welcome to the Hut eight First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during this session, you'll need to press 1 on one on your telephone. You will then hear automated message by hearing a phrase. To reply your question, please press 11 ag ...

HanesBrands (HBI) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Hanesbrands First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Krispy Kreme (DNUT) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Hello, everyone, and thanks for standing by. My name is Ian, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Krispy Kreme First Quarter twenty twenty five Earnings Call. I would now like to turn the call over to Alexander Eldridge, Krispy Kreme Investor Relations. Please go ahead. Speaker1 Thank you. Good morning, everyone. Welcome to Krispy Kreme's first quarter twenty twenty five ear ...

Financial Data and Key Metrics Changes - The company reported record quarterly revenue of $15 million for Q1 fiscal 2025, representing a 509% increase from $2.5 million in Q1 fiscal 2024 [21][24] - Non-GAAP gross profit reached a record $14 million, up 644% from $1.9 million in the same quarter last year [24] - The net loss for Q1 fiscal 2025 was $5.4 million, a significant reduction from a net loss of $17.3 million in Q1 fiscal 2024, marking the lowest quarterly loss since going public [24][26] - Adjusted EBITDA loss decreased by 53% to $6.1 million from $12.9 million year-over-year [24] Business Line Data and Key Metrics Changes - Bookings for Q1 were $1.6 million, down 64% from $4.5 million in Q1 fiscal 2024, with professional services bookings comprising over 50% of the total [22] - The company has 133 customers, including 69 commercial customers, with 36% being Forbes Global 2000 companies [23] Market Data and Key Metrics Changes - The company has seen a 153% increase in website traffic from October 2024 to March 2025, and media coverage increased by 803% from February to March 2025 [18] Company Strategy and Development Direction - The company aims to be the first independent publicly held quantum computing company to achieve sustained profitability with less funding than competitors [25] - The focus is on enhancing blockchain security and efficiency through quantum computing, with ongoing discussions for partnerships in this area [8][43] - The company is progressing on its product roadmap, targeting general availability of the Advantage 2 quantum computer by the end of the quarter [9][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's technology and commercial opportunities, highlighting the strong interest in quantum computing solutions [19][102] - The company is optimistic about the future, citing increased customer engagement and interest in quantum applications [19][102] Other Important Information - The Advantage 2 quantum computer has achieved significant technical milestones, including calibration of 4,400+ qubit processor chips and successful quantum error mitigation [9][10] - The company has completed the physical assembly of the Advantage 2 system at Davidson Technologies, with installation nearing completion [11] Q&A Session Summary Question: Clarification on Davidson Technology - Management clarified that the Davidson system is not part of previously mentioned system sales and is focused on developing applications for the US government [30][32] Question: Error Correction and Cryogenic Control - Management stated that the company is a leader in cryogenic control, operational today, while error correction for gate model systems is still under development [36][39] Question: Blockchain Application Partnerships - Management indicated that they are open to partnerships with organizations that specialize in blockchain, emphasizing the potential for enhancing security and efficiency [42][43] Question: System Sale Pricing and Pipeline Activity - Management noted that while the gross margin from the recent system sale is a good proxy, each deal will have unique elements [45][47] - The sales pipeline is healthy, with increased activity from larger organizations, although longer procurement processes are expected [50] Question: Revenue Per Customer Growth - Management observed that initial applications often lead to multiple opportunities, with larger companies engaging for proof of concept [60][62] Question: Future Profitability and Revenue Run Rate - Management did not provide specific revenue run rate estimates for achieving profitability but confirmed sufficient liquidity to reach that point [63]

NCR Voyix (VYX) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Sarah Jane Schneider - VP - IRJames Kelly - President, CEO & DirectorNick East - EVP & Chief Product OfficerBenny Tadele - EVP & President, RestaurantsDarren Wilson - EVP & President, Retail and PaymentsBrian Webb-Walsh - Executive VP & CFODan Perlin - Managing DirectorErik Woodring - Managing Director - Equity ResearchWill Nance - Vice President Conference Call Participants Matt Summerville - Managing Director & Senior Rese ...

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $203 million, representing a 3% increase compared to the prior year [26] - Adjusted EBITDA was $69.8 million, an 11% increase year-over-year, with an adjusted EBITDA margin of 34.4%, improving by 60 basis points from the previous quarter [26] - The company ended the quarter with $301 million in cash and $91.7 million of unused capacity on its revolving line of credit, resulting in total liquidity of $392.7 million [27] Business Line Data and Key Metrics Changes - Prescription transaction revenue increased by 217% year-over-year [26] - The integrated savings program (ISP) saw a decline in monthly active consumers (MACs) due to some price increases, but the company maintained its leadership position in the prescription affordability segment, with a segment share increase of over 300 basis points year-over-year in the first two months of the quarter [16][26] Market Data and Key Metrics Changes - Over 12 million consumers and over 750,000 healthcare professionals (HCPs) used GoodRx in the first quarter, indicating strong platform engagement [10] - The company acknowledged ongoing uncertainty in the macroeconomic environment, including regulatory changes and consumer sentiment shifts, which could impact business [12] Company Strategy and Development Direction - The company is focused on high-impact initiatives to strengthen its position in the pharmacy ecosystem, including enhancing partnerships with retail pharmacies and expanding its e-commerce capabilities [8][10] - GoodRx aims to serve as a digital front door for retail pharmacy partners, facilitating tighter partnerships and improving workflows [35] - The company is also investing in its brand to ensure it remains the primary choice for medication access and affordability [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the complexities of the prescription medication landscape and emphasized the importance of partnerships with pharmacies and manufacturers [10][12] - The company is aware of the potential impact of Rite Aid's bankruptcy on its business but believes it is well-positioned to manage the transition of prescriptions to other pharmacies [29][46] Other Important Information - GoodRx was recognized as one of Newsweek and USA Today's 2025 most trusted brands, reinforcing its value proposition to consumers [14] - The company is actively engaging with pharmacy partners to ensure smooth transitions for patients affected by retail closures [13] Q&A Session Summary Question: What are the most important high-impact initiatives for the company? - Management highlighted closer partnerships with retail pharmacies and expanding brand partnerships as key initiatives to drive growth [35] Question: How does the company plan to manage the impact of Rite Aid's bankruptcy? - Management stated that they are in discussions with retail partners to ensure a smooth transition for affected prescriptions and emphasized that the impact on revenue is expected to be less than 5% [29][46] Question: What is the company's perspective on the shift to cost-plus pricing by larger PBMs? - Management indicated that a significant portion of their business already operates on cost-plus pricing and that this shift does not significantly impact their cash prescription opportunities [54] Question: Is there still an opportunity with GLP medications? - Management confirmed that opportunities with GLP medications remain and that they are in discussions with manufacturers to embed their programs on the GoodRx platform [58][60] Question: How does the company view its capital allocation strategy? - Management stated that they will continue to invest in the business while also prioritizing stock repurchases due to the undervalued stock price [87] Question: What is the company's exposure to Medicare beneficiaries? - Management noted that less than 30% of users are Medicare eligible, and only 2-3% hit their maximum out-of-pocket, indicating limited impact from changes in Medicare policies [94][96]

NeueHealth (NEUE) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants George Mikan - Vice Chairman, CEO & PresidentJay Matushak - Chief Financial Officer Operator Good morning, and welcome to New Health's First Quarter twenty twenty five Earnings Conference Call. As a reminder, this call is being recorded. Leading the call today are New Health's President and CEO, Mike Mikan and CFO, Jay Matuszak. Before we begin, we want to remind you that this call may contain forward looking statements un ...

Financial Data and Key Metrics Changes - Insmed reported strong commercial performance with ARIKAYCE achieving double-digit year-over-year revenue growth in Q1 2025, marking the sixth consecutive quarter of such growth [6][25] - The company maintains its full-year ARIKAYCE net revenue guidance of $400 to $425 million, excluding any contributions from brensocatib if approved [26] - As of the end of Q1 2025, Insmed's cash balance stood at approximately $1.2 billion, positioning the company well for upcoming clinical and commercial catalysts [26][28] Business Line Data and Key Metrics Changes - ARIKAYCE experienced a 14% growth in the U.S. market, with Japan and Europe showing impressive growth rates around 50% [25][26] - The company is advancing three mid to late-stage programs: brensocatib, TPIP, and ARIKAYCE, with all programs on or ahead of schedule [6][7] Market Data and Key Metrics Changes - The disease state awareness website for bronchiectasis received over one million unique visits, indicating strong patient interest and engagement [10] - Insmed has successfully engaged with over 27,000 healthcare professionals in the U.S. regarding bronchiectasis and ARIKAYCE [10] Company Strategy and Development Direction - Insmed is focused on a frictionless launch for brensocatib, aiming for easy access and rapid uptake among patients [41][96] - The company is expanding its U.S. manufacturing footprint to mitigate tariff impacts and ensure a robust supply chain for brensocatib [24][81] - Insmed is also exploring next-generation DPP1 inhibitors for conditions like COPD and rheumatoid arthritis, indicating a commitment to addressing unmet medical needs [70][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming FDA decision on brensocatib, expected by August 12, 2025, and highlighted the positive reception from regulatory authorities [6][9] - The company is well-positioned to thrive amid geopolitical uncertainties, with minimal tariff exposure anticipated [23][24] Other Important Information - Insmed's operating expenses for Q1 2025 were consistent with historical performance, with a cost of product revenues at 22.9% of revenues [29] - The company announced the calling of $570 million of convertible debt, which could lead to the issuance of approximately 17.8 million additional shares if converted [28] Q&A Session Summary Question: What factors influence brensocatib pricing in the U.S. and abroad? - Management indicated that pricing flexibility exists due to the sequential pricing strategy across regions, allowing for adjustments based on market conditions [36] Question: What trends are observed from the bronchiectasis disease awareness website? - There is a favorable backdrop with high patient interest and enthusiasm, paralleling physician engagement [40] Question: What are the key levers for transitioning interested patients to therapy? - The focus is on connecting diagnosed patients with treatment, particularly those with two or more exacerbations [46] Question: How does the company view the importance of PVR versus six-minute walk in TPIP trials? - PVR is considered the most definitive measure, while six-minute walk is viewed as a less specific but still relevant measure [58] Question: What is the status of inspections related to brensocatib's review? - No surprises were reported from the mid-cycle review, and inspections are ongoing as part of the approval process [75] Question: Can you clarify the patient population for bronchiectasis in the U.S.? - Approximately 500,000 patients are diagnosed with bronchiectasis, with about half having had two or more exacerbations in the last twelve months [90]